Related Experiment Video

Updated: Aug 26, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells

I N Hahntow1, F Schneller, M Oelsner

  • 1Department of Medicine, Technical University of Munich, Munich, Germany.

Leukemia
|February 20, 2004
PubMed

Insights

Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, effectively induces apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells without harming normal B cells. This CDK inhibitor shows promise for treating B-CLL, an incurable disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell cycle inhibitors targeting cyclin-dependent kinases (CDKs) are a new class of drugs entering clinical trials.
  • These inhibitors induce cell cycle arrest and apoptosis in cancer cells.

Purpose of the Study:

  • To evaluate the efficacy of Roscovitine, a CDK2 inhibitor, in inducing apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
  • To assess the differential effects of Roscovitine on B-CLL cells versus normal human B cells.

Main Methods:

  • Treatment of B-CLL cells with Roscovitine (20 microM) and assessment of apoptosis.
  • Analysis of caspase-3 cleavage, expression of proapoptotic (Bak, Bax) and antiapoptotic (Mcl-1, XIAP, Bcl-2) proteins.
  • Investigation of p53 nuclear accumulation post-treatment.

Main Results:

  • Roscovitine induced apoptosis in 21 of 28 B-CLL samples, irrespective of Zap-70 status.
  • Apoptosis was mediated by caspase-3 activation and modulated by Bak, Bax, Mcl-1, and XIAP.
  • Roscovitine was not cytotoxic to normal human B cells and did not cause p53 nuclear accumulation in B-CLL cells.

Conclusions:

  • Roscovitine demonstrates potent apoptosis-inducing activity in both Zap-70-positive and -negative B-CLL cells.
  • The drug exhibits selectivity, sparing normal lymphocytes from cytotoxicity.
  • Roscovitine represents a potential therapeutic candidate for B-CLL, an incurable hematologic malignancy.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...